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Clinical and Immunological Responses in Ocular Demodecosis
The purpose of this study was to investigate clinical and immunological responses to 
Demodex on the ocular surface. Thirteen eyes in 10 patients with Demodex blepharitis and 
chronic ocular surface disorders were included in this study and treated by lid scrubbing 
with tea tree oil for the eradication of Demodex. We evaluated ocular surface 
manifestations and Demodex counts, and analyzed IL-1β, IL-5, IL-7, IL-12, IL-13, IL-17, 
granulocyte colony-stimulating factor, and macrophage inflammatory protein-1β in tear 
samples before and after the treatment. All patients exhibited ocular surface 
manifestations including corneal nodular opacity, peripheral corneal vascularization, 
refractory corneal erosion and infiltration, or chronic conjunctival inflammatory signs 
before treatment. After treatment, Demodex was nearly eradicated, tear concentrations of 
IL-1β and IL-17 were significantly reduced and substantial clinical improvement was 
observed in all patients. In conclusion, we believe that Demodex plays an aggravating role 
in inflammatory ocular surface disorders.
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Demodex (class Arachnida, superorder Acariformes) is an elon-
gated ectoparasite found on the human body surface including 
the face, cheeks, forehead, nose, and eyelids (1). There are many 
species of Demodex, but only D. folliculorum and D. brevis are 
found on the human body (2). In the eye, Demodex can be found 
on the eyelashes, the lash follicles, and the meibomian glands, 
and is thought to be associated with blepharitis, allergic conjunc-
tivitis, and pathological corneal features (2-5). Recently, a high 
prevalence of Demodex in eyelashes with cylindrical dandruff 
has been reported and a method of evaluating ocular demode-
cosis by sampling and counting Demodex has been introduced 
(6, 7). In addition, Gao et al. (8, 9) reported the ocular Demodex-
killing effects of tea tree oil (TTO) in vitro and in vivo, and intro-
duced a new clinical treatment, lid scrubbing with TTO, that has 
proven effective for eradicating ocular demodecosis. Neverthe-
less, the pathogenesis of Demodex on the ocular surface remains 
unclear up to recently. It has been merely presumed that inflam-
matory or specific immune reactions may be associated with 
ocular demodecosis (4, 9). 
  Therefore, we evaluated the changes of the clinical manifesta-
tions and the levels of tear cytokines following the eradication 
of Demodex to verify its pathogenicity, and to investigate the 
mechanisms of immunological response against Demodex on 
the ocular surface. 
MATERIALS AND METHODS
Patients 
Thirteen eyes with ocular demodecosis and chronic ocular sur-
face disorders of 10 patients were enrolled in this study. The 10 
patients included six women and four men, with an average age 
of 48.3 ± 18.9 yr (range, 14 to 70 yr). Demographic and other clin-
ical features are summarized in Table 1. 
  All patients reported ocular surface irritation and showed signs 
of ocular surface inflammation including conjunctival injections 
lasting over six months despite extensive patient-specific treat-
ment including preservative-free artificial tears, corticosteroids, 
autologous serum, acyclovir (only for herpetic keratitis), antibi-
otics, or lid scrubbing with baby shampoo. The medical records 
of all patients, including history of present illness and systemic 
diseases, were reviewed. All of the 10 patients underwent com-
plete ophthalmologic examinations, including external photo-
graphs, microscopic Demodex examination, and tear sampling. 
The patients were treated with a four-week regimen of lid scrub-
bing with TTO for ocular demodecosis and maintained prior 
topical treatments during that time. Four weeks after the initia-
tion of treatment, we compared ocular surface manifestations, 
Demodex counts, and levels of inflammatory cytokines in tear 
samples measured before and after treatment. Kim JH, et al.  •  Clinical and Immunological Responses in Ocular Demodecosis
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Microscopic Demodex examination
Ocular demodecosis was confirmed by microscopic examina-
tion of epilated lashes following the method described by Gao 
et al. (8) with some modifications. Briefly, two lashes with cylin-
drical dandruff per lid were sampled and were placed separate-
ly on a glass slide. Under a slit-lamp light microscope at a mag-
nification of × 16, one drop of 20 μL saline was applied by pipette 
to the edge of the glass slide for lashes without retained dandruff. 
For lashes with retained heavy dandruff, 20 μL of 100% alcohol 
was added. For the former, the number of Demodex was count-
ed immediately and for the latter the counting time was delayed 
up to 20 min to allow the cylindrical dandruff to dissolve and to 
stimulate the migration of embedded Demodex. The Demodex 
count was recorded as the total number of mites found in a to-
tal of four lashes per eye. 
Treatments of ocular demodecosis
Weekly lid scrubs with 50% TTO were performed and daily lid 
scrubs with 10% TTO shampoo were advised for a minimum of 
four weeks, according to the method reported by Gao et al. (9). 
In brief, at the clinic, after a drop of 0.5% proparacaine, a cotton 
tip wetted in 50% TTO was used to scrub the lid margin and lash 
roots for three sessions with a 10-min interval between each 
scrub. The patients were instructed to continue scrubbing daily 
at home, and advised to close their eyes and massage their lids 
with medium pressure for three to five minutes using a cotton 
tip wetted in 10% TTO shampoo. After treatment, the skin was 
rinsed with clean water and dried with a towel. We advised pa-
tients to perform home lid scrubs twice daily.
Tear collection and multiplex bead immunoassay 
Unstimulated tear fluid was collected from the inferior meniscus 
of each eye with the least possible irritation using a pre-weighed 
polyester wick (Transorb rods; American Filtrona, Richmond, 
VA, USA) to obtain tear samples, as previously described (10). 
Wicks were then placed into the end of a micropipette tip locat-
ed within a 0.5 mL tube (Eppendorf, Fremont, CA, USA). The 
tear samples were immediately transported in an insulated cool-
er to a -80°C freezer where they remained frozen until they were 
used for immunoassays. Tears were extracted from the saturat-
ed wicks by adding a volume of buffer (50 mM Tris/HCl, 0.15 M 
NaCl, 10 mM CaCl2, 0.005% Brij35, 0.02% sodium azide [pH 7.5]) 
10 times greater than the original volume of the tear sample to 
the pipette and then centrifuging at 12,000 rpm for five minutes. 
The rods and pipette tips were carefully removed and the tear 
fluid aspirated. Cytokines and chemokines in these samples 
were analyzed using a Luminex
® 200
TM Total System (Invitro-
gen
TM, Carlsbad, CA, USA). The cytokines and chemokines ana-
lyzed included: IL-1β, IL-5, IL-7, IL-12, IL-13, IL-17, granulocyte-
colony stimulating factor (G-CSF), and macrophage inflamma-
tory protein-1β (MIP-1β). The concentrations of these factors in 
tears were calculated from standard curves of known concen-
trations of recombinant human cytokines.
Statistical analysis
Summary data are expressed as means ± standard deviation (SD), 
analyzed by SPSS (version 13.0; SPSS, Inc., Chicago, IL, USA). 
Pre-treatment and post-treatment parameters were evaluated 
by Wilcoxon signed-rank test, and P < 0.01 was considered sta-
tistically significant.
Ethics statement
The institutional review board of Chung-Ang University Hospi-
tal approved this study (2001-022-10) and all patients provided 
informed consent. 
Table 1. Demographic and clinical features of patients with Demodex blepharitis and chronic ocular surface disorders
Case No. Sex Age (yr) Eye Combined ocular diseases Ocular surface manifestations
Demodex count*
Before TTO  After TTO 
  1 F 33 Right Atopic keratoconjunctivitis  Corneal opacity, erosion, and peripheral  
vascularization, conjunctival papillary hypertrophy
  4 0
  2 F 14 Both Atopic keratoconjunctivitis  Corneal opacity, erosion, and peripheral  
vascularization, conjunctival papillary hypertrophy
  4 0
  3 F 43 Both Allergic conjunctivitis  Corneal opacity, infiltration, and peripheral  
vascularization, conjunctival papillary hypertrophy
  2 0
  4 M 60 Left Previous herpetic stromal keratitis  Corneal opacity and erosion 10 1
  5 M 50 Left Previous herpetic stromal keratitis Corneal opacity, erosion, and peripheral  
vascularization
  2 0
  6 M 70 Left Allergic conjunctivitis  Corneal opacity and peripheral vascularization,  
conjunctival papillary hypertrophy
  6 1
  7 M 65 Right Severe dry eye  Corneal opacity and infiltration    2 0
  8 F 28 Right Allergic conjunctivitis  Corneal erosion, conjunctival papillary hypertrophy   2 0
  9 F 50 Both Previous herpetic stromal keratitis Corneal opacity and erosion   4 0
10 F 70 Left Severe dry eye Corneal opacity, erosion, and peripheral  
vascularization
  4 1
*The Demodex count was recorded as the total number of mites found in a total of four lashes per eye.Kim JH, et al.  •  Clinical and Immunological Responses in Ocular Demodecosis
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RESULTS
Ocular surface manifestations and Demodex count
Demodex was found in all patients (Fig. 1). All patients reported 
ocular surface discomfort lasting over six months. They showed 
ocular surface manifestations including large corneal nodular 
opacity (four eyes; Fig. 2A-C), refractory corneal erosion and in-
filtration (12 eyes; Fig. 2D-F), peripheral corneal vascularization 
(6 eyes; Fig. 2C, G, H), chronic palpebral conjunctival papillary 
hypertrophy (7 eyes; Fig. 2I), and chronic bulbar conjunctival 
injection (13 eyes). Three eyes had atopic keratoconjunctivitis, 
four eyes had allergic conjunctivitis, and two eyes had severe dry 
eye syndrome (dysfunctional tear syndrome level 3) (11). Four 
eyes had had herpes simplex stromal keratitis in the past. 
  After four weeks of weekly lid scrubs with 50% tea tree oil and 
daily lid scrubs with tea tree shampoo, the disappearance of dan-
druff was noted in all patients’ eyelashes. Demodex was com-
pletely eradicated in 10 of 13 eyes. The mean Demodex count 
per eye was reduced significantly, from 3.8 ± 2.2 to 0.2 ± 0.4 at 
four weeks after the initiation of treatment (Table 2; P = 0.001). 
All patients showed improvement of bulbar conjunctival injec-
tion (13 eyes), conjunctival papillary hypertrophy (7 eyes), and 
corneal erosions and infiltrations (12 eyes). Peripheral corneal 
vascularizations and nodular corneal opacities were markedly 
faded in three of six eyes and two of four eyes (Fig. 3). 
Tear concentrations of inflammatory cytokines
The mean tear concentrations of all inflammatory cytokines be-
fore and after treatment are presented in Table 2. Tear concen-
trations of IL-1β (P = 0.001) and IL-17 (P = 0.001) were signifi-
cantly reduced after treatment. Tear concentrations of IL-5, IL-
7, IL-12, IL-13, G-CSF, and MIP-1β were also reduced after treat-
ment, but the reductions were not statistically significant (P > 0.01). 
DISCUSSION
This study demonstrates that the clinical manifestations of ocu-
lar demodecosis are considerably improved and the tear levels 
of IL-1β and IL-17 are significantly decreased after eradication 
of Demodex. Previously, several studies have reported that De-
modex may cause ocular surface inflammation and pathologi-
cal features and that lid scrubbing using tea tree oil was an effec-
tive method for eradicating Demodex (4, 8, 9). Similarly, we ob-
served chronic refractory pathological ocular surface appear-
ances (such as large corneal nodular opacity, corneal vascular-
ization, severe corneal erosion and infiltration, and conjuncti-
val inflammatory reactions) in patients with ocular demodeco-
sis, and we confirmed the clinical improvement of ocular mani-
festation after the treatment of demodecosis in this study. 
  All patients in our study had not only intractable ocular sur-
face manifestations but prior inflammatory ocular surface dis-
Table 2. The mean Demodex count and tear concentrations of cytokines (pg/mL) in eyes with Demodex blepharitis and chronic ocular surface disorders before and after lid scrub 
treatment with tea tree oil
Demodex 
count*
IL-1β  IL-5  IL-7  IL-12 IL-13  IL-17  G-CSF  MIP-1β

































† 0.001 0.001 0.29 0.09 0.25 0.10 0.001 0.69 0.06
*The mean Demodex count per eye; 
†Wilcoxon signed-rank test. TTO, tea tree oil; G-CSF, granulocyte-colony stimulating factor; MIP-1β, macrophage inflammatory protein-1β.
Fig. 1. Representative microscopic photographs of Demodex folliculorum in patients with ocular demodecosis. Two D. folliculorum with an eyelash (A, arrows) and one free D. 
folliculorum are found in epilated eyelashes of patients. 
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orders including herpetic stromal keratitis, atopic keratoconjunc-
tivitis, allergic conjunctivitis, and severe dry eye. Recommend-
ed conventional treatment was not successful but the eradica-
tion of Demodex improved the pathological ocular surface man-
ifestations. This suggests that Demodex plays a pathological role 
or at least an aggravating role in inflammatory ocular surface 
disorders, especially immunological disorders. Type III or type 
IV hypersensitivity immune response is an important patholog-
ical mechanism in herpetic stromal keratitis and type I hyper-
sensitivity immune responses is a primary mechanism in atop-
ic keratoconjunctivitis and allergic conjunctivitis. So we believe 
that the pathogenesis of Demodex may be associated with hy-
persensitive immune responses on the ocular surface.
  The levels of tear cytokines can be used to indicate inflamma-
tory or immunological responses on the ocular surface. In this 
study, we observed that concentrations of IL-1β and IL-17 were 




Fig. 2. Clinical features of patients with ocular demodecosis (A, case 4; B, case 5; C, case 9; D, case 1; E, case 3; F, case 7; G, case 2; H, case 6; I, case 8). Large corneal 
nodular opacity (A-C), refractory corneal erosion and infiltration (D-F), peripheral corneal vascularization (C, G, H), and palpebral conjunctival papillary hypertrophy (I) are ob-
served in patients with ocular demodecosis. 
ductions were statistically significant. 
  IL-1 is a potent inducer of other inflammatory cytokines, in-
cluding IL-6, IL-8, TNF-α, and granulocyte-macrophage colony-
stimulating factor (GMCSF), and stimulates production of colla-
genase and matrix metalloproteinase (MMP) enzymes by epithe-
lial cells, keratocytes, and inflammatory cells (12-14). IL-1 induces 
the destruction of extracellular matrix and renders inflammatory 
damage on the ocular surface. Clinically, there have been reports 
that IL-1β is present at increased levels in tears in patients suffer-
ing inflammatory ocular surface disorders such as dry eye, Sjögren 
syndrome, and keratoconjunctivitis sicca (15). It is therefore rea-
sonable to conclude that the improvements of chronic refracto-
ry corneal epithelial erosions and ocular surface inflammatory 
signs observed after eradicating Demodex reflect reductions in IL-
1. However, it is difficult to specify the particular inflammatory 
process in ocular demodecosis because IL-1 is a cytokine involv-
ed in various immune responses and inflammatory processes.Kim JH, et al.  •  Clinical and Immunological Responses in Ocular Demodecosis
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A C B
D F E
Fig. 3. Clinical appearance before and after lid scrubbing treatment with tea tree oil in patients with ocular demodecosis. (A and D, case 4; B and E, case 9; C and F, case 7). 
There are corneal nodular opacities (A, B), bulbar conjunctival injections (A, B) and central corneal infiltration (C) before the treatment. However, four weeks after the treatment, 
corneal opacities are markedly faded and conjunctival injections had resolved (D, E). Central corneal infiltration had also resolved (F). 
  IL-17 is an important cytokine in inflammatory and autoim-
mune conditions (16). It is secreted mainly by activated helper T 
cells and enhances the generation, activation, and migration of 
neutrophils through the induction of proinflammatory cytokines 
(17, 18). T cells secreting IL-17, named Th17 cells, are now con-
sidered developmentally distinct from Th1 and Th2 cells and are 
thought to play a key role in autoimmune reactions (19, 20). IL-
17 activates T cells and other immune cells to produce a variety 
of cytokines and cell adhesion molecules not only in the early 
neutrophil-mediated inflammatory response, but also in the in-
duction of both Th1-type and Th2-type immune responses (21, 
22). Synergy with other inflammatory cytokines such as IL-1β, 
tumor necrosis factor (TNF)-α, and IFN-γ leads to up-regulation 
of gene expression and progression and amplification of local 
inflammation (23, 24). Levels of IL-17 are significantly increased 
in autoimmune diseases including rheumatoid arthritis synovi-
um, asthmatic airways, during allograft rejection, and in other 
chronic inflammatory diseases including multiple sclerosis and 
psoriasis (25-28). In this study, the reduction in tear levels of IL-
17 after Demodex eradication suggests that ocular demodecosis 
is associated with elevated cell mediated immune conditions, 
especially the Th17 cell immune response. IL-17 is also a potent 
inducer of angiogenic chemokines such as vascular endothelial 
growth factor-A (VEGF-A) from a number of cells, including ke-
ratinocytes, fibroblasts and epithelial cells (29, 30). It is reason-
able to explain that decreased levels of tear IL-17 following De-
modex eradication contribute to the improvement of abnormal 
corneal vascularization. 
  There are some limitations in this study including the small 
number of subjects, the possible anti-inflammatory effect of tea 
tree oil, and the possibility of other inflammatory factors asso-
ciated with Demodex, such as bacterial distribution. Future stud-
ies should include normal control subjects or blepharitis control 
subjects without Demodex, a larger number of subjects, an as-
sessment of the anti-inflammatory effects of tea tree oil and the 
bacterial distribution in ocular demodecosis, and a wider anal-
ysis of cytokines associated with the Th17 immune response in-
cluding IL-6, IL-21, IL-22, IL-23, and transforming growth factor 
beta (TGF-β). With further study, we may be able to confirm the 
pathogenic mechanism of Demodex on the ocular surface. 
  In summary, we examined chronic refractory inflammatory 
pathological ocular surface manifestations in patients with ocu-
lar demodecosis and verified that lid scrubbing with tea tree oil 
was an effective method to eradicate Demodex leading to clini-
cal improvement. We also noted that tear concentrations of IL-
1β and IL-17 were significantly decreased after the eradication 
of Demodex in the patients. Therefore, we believe that Demodex 
plays an aggravating role in inflammatory ocular surface disor-
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Demodex is thought to be associated with blepharitis, allergic conjunctivitis, and pathological corneal features on the ocular 
surface. However, the pathogenesis of Demodex on the ocular surface remains unclear. We evaluated clinical manifestations and 
tear cytokine level changes following the eradication of Demodex on the inflammatory ocular surface disorders. After a course of 
treatment of lid scrubbing with tea tree oil in patients with ocular demodecosis, Demodex was nearly eradicated, and there was 
substantial clinical improvement and tear concentrations of IL-1β and IL-17 were significantly reduced in all patients. Therefore, 
we believe that Demodex plays an imporatant aggravating role in inflammatory ocular surface disorders.